Allogene Therapeutics
ALLO
95 hedge funds and large institutions have $1.87B invested in Allogene Therapeutics in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 10 closing their positions.
371% more call options, than puts
Call options by funds: $10.7M | Put options by funds: $2.28M
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
1% more funds holding
Funds holding: 94 → 95 (+1)
1% more capital invested
Capital invested by funds: $1.85B → $1.87B (+$22.8M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.25% less ownership
Funds ownership: 56.67% → 56.42% (-0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$14.3M |
| 3 |
BlackRock
New York
|
+$12.6M |
| 4 |
WCM
Wildcat Capital Management
New York
|
+$10.7M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$7.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VV Manager
Boston,
Massachusetts
|
-$51.2M |
| 2 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$9.43M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.39M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$6.42M |
| 5 |
DP
DSAM Partners
London,
United Kingdom
|
-$4.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MWNA
101
Marshall Wace North America
New York
| – | -$256K | -9,531 | Closed |
|
|
QT
102
Quantbot Technologies
New York
| – | -$96K | -3,600 | Closed |
|
103
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$82K | -3,067 | Closed |
|
|
PRC
104
Pearl River Capital
Niles,
Michigan
| – | -$20K | -748 | Closed |
|
105
Simplex Trading
Chicago,
Illinois
| – | -$4.47K | -157 | Closed |
|
ALLO Hedge Fund Activity: Q3 2019 in Review
95 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2019, worth a combined $1.87B — up 1.2% from $1.85B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALLO positions and 10 closed out — a net gain of 2 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Vanguard Group, adding an estimated $14.4M. The largest seller was VV Manager, cutting an estimated $51.2M.
- 95 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2019, up from 94 in Q2 2019.
- Funds reported $1.87B of Allogene Therapeutics stock for Q3 2019, up 1.2% quarter-over-quarter.
- 12 funds opened new Allogene Therapeutics positions in Q3 2019 and 10 closed out, a net change of +2 holders.
- The largest Allogene Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $14.4M added.
- The largest Allogene Therapeutics seller in Q3 2019 was VV Manager, an estimated $51.2M sold.
Based on aggregated 13F filings for Q3 2019.